Literature DB >> 1024769

Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.

N Barth, G Alván, O Borgå, F Sjöqvist.   

Abstract

Plasma protein binding of phenytoin (diphenylhydantoin) in 63 epileptic patients was investigated with an ultrafiltration technique at room temperature using 14C-labelled phenytoin. A strong correlation was found between the total and the unbound drug concentration (r = 0.97, p less than 0.001). The unbound phenytoin fraction was 7.1 +/- 1.0% with a range of 4.9 to 10.2%. This variation is considerably less than that reported recently by different authors. Individual phenytoin binding was reproducible when the determination was repeated several weeks later. Salivary phenytoin concentrations in 33 epileptic patients were significantly correlated to the unbound (r = 0.83) and total concentrations (r = 0.82) of phenytoin in plasma. This study confirms that the clinical practice of monitoring total phenytoin plasma concentrations is sufficient, since the unbound phenytoin fraction has only a 2-fold interindividual variation in epileptic patients, provided that they do not suffer from renal or hepatic disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1024769     DOI: 10.2165/00003088-197601060-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

1.  Interactions between drugs and saliva-stimulating parafilm and their implications in measurements of saliva drug levels.

Authors:  K Chang; W L Chiou
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1976-02

2.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

3.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

4.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

5.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

6.  Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid.

Authors:  L Lund; A Berlin; K M Lunde
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

7.  Morphine and phenytoin binding to plasma proteins in renal and hepatic failure.

Authors:  G D Olsen; W M Bennett; G A Porter
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

8.  Plasma albumin concentration and diphenylhydantoin binding in man.

Authors:  R J Porter; R B Layzer
Journal:  Arch Neurol       Date:  1975-05

9.  Mass fragmentographic determination of diphenylhydantoin and its main metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, in human plasma.

Authors:  C Hoppel; M Garle; M Elander
Journal:  J Chromatogr       Date:  1976-01-07

10.  The rate of decline of diphenylhydantoin in human plasma.

Authors:  K Arnold; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.903

View more
  19 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Effect of halofenate on the serum binding of phenytoin.

Authors:  F E Karch; W M Wardell; M Dambly; A Gringeri
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

Review 4.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

5.  The role of drug interactions in interindividual variability of drug metabolism in man.

Authors:  F Sjöqvist
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

6.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Monitoring free plasma concentrations of phenytoin.

Authors:  G M Peterson; S McLean
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

9.  Should we routinely measure free plasma phenytoin concentration?

Authors:  E M Rimmer; D C Buss; P A Routledge; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

10.  Comparison of phenytoin determinations in plasma, plasma dialysate and saliva for control of antiepileptic therapy in children.

Authors:  G Brügmann; E Kleinau; R Nolte; F Petruch
Journal:  Klin Wochenschr       Date:  1979-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.